GCMS-QP2020 NX

Biomarkers are derived from living organisms and found in tissues, blood, and other bodily fluids. Biomarkers are indicators of biological changes in an organism and are used to diagnose disease, in prognosis, and to evaluate the efficacy and safety of pharmaceuticals. Biomarkers can be nucleic acids, proteins, peptides, lipids, and sugars, and are identified using various “omics” techniques.

Proteomics is an academic discipline involving the comprehensive study of protein structure and function, typically by mass spectrometry and electrophoresis. Unlike the genome, the cells of an organism do not all contain the same complement of proteins, but different cells contain different proteins at different times. Proteomics uses this phenomenon to enable more efficient drug development and to determine the mechanisms of disease.

Anti-doping policies, rules and regulations are governed by the World Anti-Doping Agency (WADA). Doping is not only harmful to athletes who take performance-boosting drugs, but also affects the integrity of a sport. Shimadzu instruments can help ensure clean sports and here are a few applications.

Peakintelligence for GCMS is equipped with new AI peak integration algorithms that significantly shorten the time needed for peak integration in the GC/MS/MS quantitative processing work sequence. AI algorithms trained with peak integration know-how provide peak integration on par with that of an experienced user, so configuring or adjusting parameters is not required. In addition, the software can correctly detect low-concentration samples.

Method Package contains ready-to-use analytical conditions and sample pretreatment procedures optimized for Shimadzu mass spectrometers and specific analytical applications.